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Background: In a previous study, exhaled carbon monoxide (eCO) has been assessed in healthy non-smokers with
a photo acoustic spectrometer Brüel&Kjær 1312. Unexpectedly, values were higher than those reported in literature,
which were mostly obtained with electrochemical analysers. This study was aimed to compare eCO values obtained
with Brüel&Kjær 1312 and PiCO + Smokerlyzer, a largely utilized electrochemical analyser.
Methods: Thirty-four healthy subjects, 15 non-smokers and 19 smokers, underwent eCO assessment with Brüel&Kjær
1312 and PiCO + Smokerlyzer during a prolonged expiration (15 seconds). Brüel&Kjær 1312 assessed CO concentration
7 and 12 seconds after the beginning of expiration and displayed the mean value. PiCO + Smokerlyzer was utilized
according to the manufacturer’s recommendations. In vitro, the two devices were tested with standard concentrations
of CO in nitrogen (5, 9.9, 20, and 50 ppm), and the time needed by PiCO + Smokerlyzer readings to stabilize was
assessed at different gas flows.
Results: Both Brüel&Kjær 1312 and PiCO + Smokerlyzer presented very good internal consistency. The values provided
were strictly correlated, but at low test concentrations, the Brüel&Kjær 1312 readings were greater than the PiCO +
Smokerlyzer, and vice versa. PiCO + Smokerlyzer overestimated the CO standard concentrations at 5 and 9.9 ppm by
20%, while Brüel&Kjær 1312 measures were correct. PiCO + Smokerlyzer readings stabilized in 12 seconds during
in vitro tests and in 15 seconds during in vivo measurements, suggesting that the values displayed corresponded to
the initial phase of expiration.
Conclusions: Differences between Brüel&Kjær 1312 and PiCO + Smokerlyzer may be explained because Brüel&Kjær
1312 measured CO levels in the middle and at the end of expiration while PiCO + Smokerlyzer assessed them in the
initial part of expiration.
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Carbon monoxide (CO) is the product of the heme con-
version to biliverdin by microsomal heme oxygenase; a
further amount (about 15%) results from the degradation
of myoglobin, guanylyl cyclase, and cytochromes [1]. In the
human body, CO is not simply a waste product of heme
metabolism, but also a neurotransmitter and has important
anti-inflammatory, anti-proliferative, anti-apoptotic, and
antioxidant properties [2]. The amount of CO stored in the* Correspondence: umoscato@rm.unicatt.it
1Institute of Public Health, Hygiene Division, Catholic University “Sacro
Cuore”, Largo Francesco Vito, 1, 00168 Rome, Italy
Full list of author information is available at the end of the article
© 2014 Moscato et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.body is affected by endogenous and exogenous factors [3].
In the presence of hemolysis, the rate of heme conversion
to biliverdin increases [4]. In local and systemic inflam-
matory states, an inducible isoform of heme oxygenase
(OH-1) is synthetized, which increases the rate of heme
metabolism and, consequently, CO production. In smokers,
CO produced during the combustion of tobacco is partly
absorbed through the inhaled air [5]. Since CO is mainly
removed from the body through the lungs, its concen-
tration in the exhaled air (eCO) increases whenever one
of these conditions occurs.
Increased eCO values have been reported in systemic
diseases, such as severe sepsis [6,7], cystic fibrosis [8],l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Moscato et al. BMC Pulmonary Medicine 2014, 14:204 Page 2 of 7
http://www.biomedcentral.com/1471-2466/14/204cirrhosis [9], and after liver transplantation [10]. In-
creases have also been observed in some respiratory dis-
eases, such as asthma [11-13], inflammatory pulmonary
diseases [14], upper and lower respiratory tract infec-
tions [15,16], bronchiectasis [17], seasonal allergic rhin-
itis [18], and in lung transplantation [19], probably as
the result of local inflammation [20,21]. The potential
usefulness of eCO assessment in these conditions is in-
creased by the ease of measurement, which can be car-
ried out by portable and reasonably priced devices that
utilize electrochemical sensors and offer good levels of
sensitivity (usual determination limit: 1 ppm).
Recently, a photo acoustic spectrometer was utilized
to investigate the influence of hypoventilation and
hyperventilation on eCO levels in a group of healthy vol-
unteers [22]. Such device was chosen because it is linear
over a wide dynamic range and provides higher levels of
sensitivity (detection limit up to 0.02 ppm) than trad-
itional CO analyzers based on electrochemical sensors.
The results of the study showed that the values obtained
with the photo acoustic spectrometer, although charac-
terized by very good internal consistency, were above
the range considered normal for the CO analyzers based
on electrochemical sensors.
The aim of this study was to compare eCO measures
provided by a photoacustic spectrometer and an electro-
chemical analyzer in vivo and in vitro in order to assess
the comparability of use of the two detection systems.
Methods
Subjects
After obtaining the approval of the local Ethics Commit-
tee of the Catholic University “Sacro Cuore” and the in-
formed consent, 34 healthy volunteers (29.5 ± 6.5 years;
BMI 22.5 ± 3.7 Kg/m2) were recruited. Eight males and
11 females were current smokers (Median 10 cigarettes/
day; Range 2–30 cigarettes/day), while 7 males and 8 fe-
males were non-smokers. Non-smokers were defined as
subjects without a story of active or passive smoking in
the previous 4 months. None of the subjects had under-
gone previous eCO measurements with the two devices
tested in the study. Exclusion criteria were a medical his-
tory of acute or chronic respiratory inflammatory dis-
eases, and the ingestion of anti-inflammatory drugs
during the previous 72 hours.
Devices
The characteristics of the two devices were as follows:
a) Brüel&Kjær 1312 (B&K) (Brüel & Kjær, AirTech
Instruments, Ballerup, Denmark) is a field gas monitor
based on the photo-acoustic effect [23]. The device per-
forms a side stream analysis in a measurement chamber,
where the molecules of CO absorb energy from mono-
chromatic infrared light. Energy absorption increases thekinetic energy of the molecules and causes the generation
of sound waves, which are detected by a stable transducer
(microphone). The device is characterized by a very low
detection limit (less than 0.02 ppm) and provides auto-
matic compensation for water vapour and other gas inter-
ference, and for temperature. The gas mixture to be
analysed is aspirated into the measurement chamber at a
constant rate through a Teflon/Viton tube one meter long;
sampling begins after the washout of the dead space. For
each measurement, the operator sets the duration and
volume of sampling and the frequency of analysis. In this
study, sampling lasted 10 seconds and two measures were
performed, at 5 and 10 seconds; only the mean value was
displayed by the device. According to the manufacturer’s
recommendations, sampling volume was determined with
the following algorithm:
Total Volume ¼ V 1302 þ VPMC þ Vtube
¼ 50 mLþ 3 mLþ 7:07 mL
¼ 60:07 mL
V1302 = internal volume of the device circuits = 50 mL
VPMC = Photoacustic Measurement Chamber volume ≈
3 mL
Vtube = volume of the sampling tube = 3.14 × 0.15
2 ×
100 = 7.07 mL
b) Bedfont EC50 PiCO+ Smokerlyzer (PiCO+) (Bedfont
Scientific, Kent, UK) is a small, portable device primarily
aimed to distinguish smokers from non-smokers and to
classify smokers on the basis of their smoking habits. It
has been also utilized in many studies that investigated
eCO levels in respiratory diseases [8,9,11-18]. This instru-
ment utilizes an electrochemical sensor to analyse exhaled
air for eCO concentration and has a detection limit of
1 ppm. Displayed values increase until a stable reading is
reached. According to the manufacturer’s recommenda-
tions, in this study measurements were performed during
a sustained exhalation after a deep breath to total lung
capacity, followed by a 15 s breath-hold.
Protocol
1) In vivo comparison between B&K and PiCO+After recording demographic and anthropometric
data and medical history, all subjects underwent a
brief training on the procedure. They were asked to
perform a deep breath to total lung capacity, a 15 s
breath-hold, and a 15 s sustained exhalation through
a mouthpiece. The mouthpiece was connected
to a circuit that in the order consisted of a HME
bacterial/viral filter (DAR Barrierbac S, Mallinkrodt
DAR, Italy), a Teflon connection tube, with three
output ports, connected to: a cardboard and plastic
tube through which the exhaled gas was sent to the
PiCO+; a capnometer CosmoPlus mod. 8100
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(Figure 1). Gas sampling for B&K took ten seconds
and started 2 seconds after the beginning of
exhalation in order to discard the anatomical dead
space (such delay was chosen on the basis of
preliminary tests). Accordingly, CO concentration
was assessed seven and twelve seconds following the
beginning of expiration. During each measurement,
the operator checked that the plateau phase of the
capnogram was already started when gas sampling
began. In each subject, three valid measures by
B & K and PiCO+ were obtained.
Prior to starting the study, both B&K and PiCO+
were calibrated according to the manufacturer’s
recommendations.2) In vitro tests
A first series of measurements were performed by
connecting the previously described circuit to
cylinders that contained mixtures of CO and
nitrogen (Sapio Srl, Italy). The CO concentrations
tested were 5, 9.9, 20, and 50 ppm. The pressure of
gas outlet was set at 0.12 bar. The means of 4
measurements were calculated.
A second set of measurements was performed in
order to relate PiCO+ readings and latency to gas
flows. Measurements were performed with the
cylinder that contained 9.9 ppm of CO by varying
outlet pressure from 0.01 to 0.12 bar. Flows were
assumed to be proportional to the pressures applied
to the circuit because a linear flow could be
reasonably hypothesized. The eCO values providedre 1 Diagram of the experimental circuit and volumes of the componen
gh a circuit consisting of (A) an HME bacterial/ viral filter (DAR Barrierbac S, M
ut ports, connected to: (C) cardboard and plastic tube (D-piece) through whi
ometer CosmoPlus mod. 8100 (Novametrix Medical Systems Inc. Connecticut
irection of the arrows points out the direction of air flow.by PiCO+ and the time elapsed from the beginning
of expiration to the appearance of stable readings
were recorded.Statistics
Data are presented as means (standard deviations) or me-
dians (ranges) as appropriate. Wilcoxon signed-ranks test
was performed to test the difference between the two
instruments both in vivo and in vitro. Intraclass correl-
ation coefficients (ICCs) were utilized to compare the
measures obtained by the two devices tested. Bland-
Altman plots were also employed to describe the limits
of agreement to data with repeated measurements (for
equal numbers of replicates by each method on each
subject) [24].
Results
All subjects successfully performed three sets of mea-
surements. The mean number of attempts required to
obtain three approved measurements was 4.2 (0.9). No
adverse event was observed. Environmental CO concen-
tration measured with B&K was 1 (0.2) ppm.
1) In vivo comparison between B&K and PiCO+
Table 1 presents eCO values measured with B&K
and PiCO+. Data are stratified by gender and
smoking habit. The eCO values obtained by B&K
were significantly higher than those obtained by
PiCO+ (12.2 (7.4 – 45.3) Vs. 5.0 (1 – 51) ppm)
(p <0.01). Stratified data did not point out
differences related to gender, but values werets. The subjects enrolled in the study were asked to breathe
allinkrodt DAR, Italy); (B) Teflon connection tube, with three
ch the exhaled gas was sent to (E) PiCO + Smokerlyzer; (F)
, USA); (D) photoacoustic spectrophotometer Brüel&Kjær 1312.
Table 1 eCO values (ppm) provided by B&K and PiCO+ in
the healthy volunteers enrolled in this study
Smokers Non-smokers
Males Females Total Males Females Total
N = 8 N = 11 N = 19 N = 7 N = 8 N = 15
B&K 21.8 16.3 18.3 11.2 10.4 10.9
(31.71) (28.35) (28.35) (2.15) (4.16) (5.17)
PiCO+ 23.8 15.9 19.2 4.3 3.2 3.7
(13.27) (12.94) (13.54) (4.5) (3.4) (3.4)
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Both the devices presented an excellent internal
consistency. Intraclass correlation coefficients were
0.995 for B&K and 0.985 for PiCO+ (estimated
reliability 0.998 and 0.995). PiCO+ displayed the
initial value after 3 (1) sec and the final value after
15 (2) sec in non-smokers and after 3 (1) sec and
20 (3) sec in smokers.
The values obtained by the two instruments were
strongly correlated (Figure 2). The Bland-Altman
plot (Figure 3) showed that the relationship between
difference and mean is not linear and that the gap was
dependent on eCO levels. In particular, B&K displayed
higher values than PiCO+ at low eCO levels and lower
values at high eCO levels; measures were practically
equivalent in the interval between 20 and 40 pm.
The mean difference and the limits of agreement
for repeated measures adjusted for non uniform
differences and their 95% CI are shown in Figure 3.re 2 Correlation between eCO values (ppm), obtained with Brüel
tudy. The measures taken into account were 102 (3 measurements fo
orted.2) In vitro tests&Kjær
r eachTable 2 reports CO values provided by B&K and
PiCO+ when challenged with 4 standard CO
concentrations. At 5 and 9.9 ppm, PiCO+
overestimated CO values by about 20%, while B&K
maintained an excellent precision in the entire
range of concentrations.
The results obtained by challenging PiCO+ with a
gaseous mixture containing 9.9 ppm of CO in
nitrogen at different flow rates are reported in
Figure 4. The device overestimated CO values by
about 10% at low flows and by 20% or more at high
flows. The time needed to achieve stable readings
was 12 seconds at high flows, but increased to
19 seconds at the lowest flow tested.Discussion
In this study, B&K and PiCO+ exhibited good internal
consistency so that both are probably suitable for asses-
sing the eCO variations associated with smoking status
or diseases. Conversely, the eCO values obtained with
the two devices were significantly different, even if they
correlated very well. In particular, the B&K readings
were greater than the PiCO+ at low test concentrations,
and vice versa. This finding suggests that eCO values
obtained with B&K and PiCO+ are not comparable and
that the normal range is different.
Discrepancies between B&K and PiCO+ are hardly
explained by the higher accuracy of the former because
in vitro tests showed that PiCO+ overestimated CO
values at low concentrations. Conversely, our data sug-
gest that the values provided by the two devices may1312 and PiCO + Smokerlyzer, in the subjects enrolled in
of 34 subjects). The Identity line (Y = X; grey dashed line)
Figure 3 Agreement between Brüel&Kjær 1312 (eCOBK) and PiCO + Smokerlyzer (eCOPiCO) (Bland Altman plot). The measures taken
into account were 102 (3 measurements for each of 34 subjects). The regression line for the mean agreement (Y = −0.3336 X −9.192) is reported.
The coefficient of determination R2 was ≈ 0.7214 (p = 0.000). The standard deviation of the residuals is 2.2716; there is no significant relationship
between the standard deviation of the differences and the average of the two methods (p = 0.165). To consider the repeated measures approach
and the non linear relationship between difference and mean, the Limits of Agreement (LOA) was evaluated modelling the variability in the
Standard Deviation of the mean difference directly as a function of the level of the measurement.
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regard, B&K assessed eCO concentration 7 and 12 sec-
onds after the beginning of expiration, i.e. in the middle
and at the end of expiration, and displayed the mean of
the two values. PiCO+ specifications do not report to
which phase of expiration the displayed values correspond.
In this study, the time needed to achieve stable readings
was 12 seconds or more after the beginning of gas chal-
lenge during in vitro tests and about 15 seconds after the
beginning of expiration in measurements performed on
healthy volunteers. These findings suggest that the eCO
concentration measured by PiCO+ corresponds to in the
initial phase of expiration, when flow is maximum.
In most studies, eCO values have been measured with
electrochemical devices, which are cheaper and more
easily transportable than laser spectrophotometers, near-
infrared analysers [25,26] or photo acoustic spectrometers
[22]. Among electrochemical devices, PiCO+ has been
utilized both for monitoring smoking habits (which isTable 2 In vitro CO measures (ppm) provided by B&K and
PiCO+ on four standards
Standard B&K PiCO+ P
5 ppm 5.1 (0.1) 6.7 (0.4) <0.01
9.9 ppm 10.00 (0.1) 12.0 (0.9) <0.05
20 ppm 19.00 (0.1) 18.5 (0.6) 0.59
50 ppm 47.9 (0.2) 47.0 (1.0) 0.28
Means (standard deviations) of three values are reported.its primary target) [27-29] and for assessing eCO levels
in several diseases [8,9,11-17]. Normal eCO values were
not exactly comparable even across studies that utilized
this device, since mean values in non-smoker subjects
varied from less than 1.5 [15] to 3 ppm [17]. Factors
that have been proposed to explain such variability were
differences in environmental CO levels, in anthropometric
characteristics such as lung capacity [30] and in measure-
ment techniques. In this regard, measures achieved during
prolonged expirations provide values higher than those
obtained during shorter ones [31]. High environmental
CO levels can probably explain the eCO levels observed in
the non smoker participants in this study (mean value
3.7 ppm) because they all lived in a big city and travelled
through traffic to get to the University. A further factor
that should be considered is the trend of eCO concentra-
tion during expiration, which has been divided in three
phases by Schober et al. [32]. Exhaled CO concentration is
zero in the initial part of the expiration (phase 1), then it
increases progressively (phase 2), until a plateau is reached
(phase 3). Of note, phase 2 is much less steep than in
capnograms, suggesting that it may be influenced by
alveolar inhomogeneities since gas from the alveoli with
a longer time constant mostly contribute to the final
part of expiration [33]. Interestingly, phase 3 mean eCO
concentration measured by Schober et al. in a group of
healthy, non-smoker volunteers, was 10.7 ppm [32], a
value similar to that provided by B&K in the healthy
non smoker subjects included in this study (10.9 ppm).
Figure 4 Readings and latencies of PiCO + Smokerlyzer challenged with CO standard (9.9 ppm) at different flow rates. Latency
corresponded to the time elapsed from the beginning of expiration to the appearance of stable readings. Flows were assumed to be
proportional to the pressures applied to the circuit because a linear flow could be reasonably hypothesized.
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obtained with one device not comparable with those
obtained with the other. According to our hypothesis,
the values provided by B&K may be more informative
of the alveoli with a slower time constant while those
obtained with PiCO+ are probably unaffected by them.
Conversely, according to the latency of 15 seconds ob-
served in healthy volunteers, the values shown by PiCO+
might even refer to phase 2 of CO expiratory trend. In
this regard, alveolar inhomogeneities about CO content
are probably negligible to detect smoking habit because
smokers present increased eCO levels throughout the
expiration. By contrast, it is not clear whether initial,
mean and end tidal eCO values are equally effective as
markers of respiratory or systemic diseases, so that fur-
ther studies are needed. Finally, it is not clear why PiCO
+ displayed eCO values lightly higher than those dis-
played by B&K above 30 ppm. Since the tests in vitro
showed a good accuracy of both devices at those CO
levels, the difference of values may hypothetically ori-
ginate from a different trend of eCO concentration dur-
ing deep expiration in heavy smokers. Our data suggest
that PiCO+ readings can be influenced by the flow of
gas through it. The more the flow, the higher the value.
Hypothetically, if phase 2 is shorter in heavy smokers,
readings of PiCO+ may occur at the time of maximum
eCO values and maximum gas flow and this may lead to
the reversal of the difference with B&K. Unfortunately,
no data are available in literature in this regard.
This study has some limits. B&K and PiCO+ were only
compared in healthy subjects and potential differences
related to the presence of respiratory diseases were notinvestigated. Besides, the devices and the circuit utilized
did not allow isolate measurements of eCO concentra-
tion in the last part of expiration. Finally, the devices
were not compared in vivo in static conditions, for in-
stance by collecting exhaled gas in a bag. That com-
parison was deemed unnecessary because the accuracy
of the detectors was assessed in vitro with constant gas
flows.
Conclusions
B&K and PiCO+ can be both utilized to measure eCO
because they exhibited good internal consistency and
the measures obtained correlated very well. Nonetheless,
values obtained with these devices are not comparable to
each other and normal ranges do not coincide. Differences
are probably explained because PiCO+ assesses eCO con-
centration in an earlier stage of expiration than B&K,
which performs the analysis in the middle and at the end
of expiration. Further studies are needed to evaluate which
measurement technique is more effective to investigate
the eCO variations induced by respiratory diseases.
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